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CNS gene transfer could provide new approaches to the modelling of neurode-
generative diseases and devising potential therapies. One such disorder is Par-
kinson’s disease (PD), in which dysfunction of several different metabolic pro-
cesses has been implicated. Here we review the literature on gene transfer sys-
tems based on herpes simplex virus type 1 (HSV-1) and non-viral
polyethyleneimine (PEI) and calcium phosphate nanoparticle methods. We also
assess the usefulness of various CNS gene delivery methods and present some
of our own data to exemplify such usefulness. Our data result from vectors
stereotaxically introduced to the substantia nigra (SN) of adult rats and evaluat-
ed 1 week and/or 1 month post injection using histochemical methods to assess
recombinant b-galactosidase enzyme activity. Gene transfer using PEI or calcium
phosphate-mediated transfections was observed for both methods and PEI was
comparable to that of HSV-1 amplicon. Our data show that the amplicon deliv-
ery was markedly increased when packaged with a helper virus and was similar
to the expression profile achieved with a full-size replication-defective HSV-1
recombinant (8117/43). We also examine whether PEI or HSV-1 amplicon-medi-
ated gene transfer could facilitate assessment of the biological effects induced
by a dominant negative FGF receptor-1 mutant to model the reduced FGF sig-
nalling thought to occur in Parkinson’s disease.
Key words: Parkinson’s disease, fibroblast growth factor, substantia
nigra, gene transfection, herpes simplex virus-1, polyethyleneimine,
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INTRODUCTION
The in vivo introduction of genes into the brain
and spinal cord is a challenging task, which holds
promise for unravelling the functions of specific
genes, modelling diseases by delivering “pathologi-
cal” genes, and also for reversing the detrimental
effects of missing or defective genes. Because of this
promise, the search for effective and reliable in vivo
gene transfer techniques is an ongoing endeavour.
Remarkably, the injection of DNA plasmid alone,
directly into animal foetuses, has been shown to have
a greater than 20% integration and transcription of
the reporter gene in the gonad, gut, liver, spleen,
lung and brain tissue [20]. Unfortunately, gene trans-
fer into the adult mammalian brain using this meth-
od has met with little success. In facilitating this trans-
fection, various chemical and viral methods have
proven to varying degrees effective.
Facilitation of gene transfer using cationic lipo-
some-mediated transfection of plasmids containing
the lacZ gene into the caudate-putamen of adult mice
has been reported, with expression lasting at least
21 days post transfection [50]. However, the efficien-
cy of this method for in vivo work is low, with typical
results showing only several weakly stained cells in
the brain region adjacent to the injection site [33].
A similar, but more successful agent is PEI, which
is an effective gene transfection agent even in the
adult mammalian brain [8]. Every 3rd atom in PEI
molecule is a protonable amino nitrogen atom, which
makes the polymeric association with negatively
charged DNA an effective “proton sponge”. This al-
lows for endosome buffering and thus protects DNA
from lysosomal degradation. PEI can exist as either
a linear or a branched polymer, although the linear
PEI of 25 kDa or less seems to be the most effective [1].
One example of this is a report documenting the
linear form to be better for transfections into tu-
mours [15]. Another example shows success using
linear 22 kDa PEI to transfect neurons and glia adja-
cent to the ventricular system following intraventric-
ular injections (in mice) [22] and in the xenopus tad-
pole brain [45]. In the latter case, intraventricular
microinjections of 1 microlitre (containing 0.5 to
1 microgram DNA) showed that the linear low mo-
lecular weight polymer 22 kDa PEI was significantly
more efficient than a branched 25 kDa polymer [45].
In mice intraventricular injections of PEI/DNA with
lacZ reporter (beta-galactosidase gene) by cre-recom-
binase to R26R mice demonstrated survival and mi-
gration of stem cell derivatives 3 months after injec-
tion [36]. The solvent vehicle used for PEI is also im-
portant since the salt-free linear PEI22/DNA is about
10–100 times more effective than the branched PEI/
/DNA and salt-containing PEI22/DNA complexes [71].
Another well-proven method is the calcium phos-
phate precipitate method, which has been widely
used for in vitro transfection, owing to the ability of
calcium ions to complex with plasmid DNA as well
to form ion-channels in cell membranes [23, 66].
Unfortunately, owing to the bulk size of these com-
plexes and the inadequate protection of plasmid DNA
from enzymatic digestion, early experiments in vivo
did not enjoy great success. However, an improve-
ment on this technique used nanoparticles of calci-
um phosphate to accomplish both in vitro and in
vivo transfection [51]. This improvement is probably
due to the encapsulation of the plasmid DNA; thus
protecting it from enzymatic digestion. A very re-
cent report stated that the in vitro transfection effi-
ciency of 100–120 nm diameter calcium phosphate
nanoparticles was higher than that of commercial
transfecting reagents [5]. Finally, recent studies have
shown that by functionalising the nanoparticles with
appropriate ligands, the system can be targeted to
selected cell types in vivo [51]. These properties, cou-
pled with the biodegradability of calcium phosphate,
prompted us to investigate this system for deliver-
ing foreign genes into the brain.
In considering viral methods, Herpes Simplex
Virus-1 (HSV-1) is a particularly useful vector for deliv-
ering and expressing foreign genes within CNS.
This neurotropic virus possesses a complex genetic
program that leads to it spending most of its life
cycle within the nervous system [58, 68]. HSV-1 en-
ters neurons at the periphery and travels via axonal
transport to cell bodies of the sensory ganglia, where
it becomes latent [58, 68]. One of the promising HSV-1
vectors is an ICP4-replication deficient virus recom-
bined with a HSV latency-associated transcript pro-
motor (LAT) and the Moloney murine leukemia virus
LTR (LAT/LTR) fused with the coding sequence for E. coli
lacZ gene (ICP4-LAT/MoMuLVLTR/b-gal cassette) [7].
This vector has been shown to transfect both the
hippocampus and SN [59].
An alternative and simpler vector platform is
HSV-1 amplicon, a drastically minimised derivative
of the replication-defective full size recombinant HSV-1
vectors. These vectors are transfected into packag-
ing cells, in which, through complementation with
a replication-defective helper virus or a bacterial ar-
tificial chromosome carrying a pac-deficient HSV ge-
nome, viral particles are assembled [11, 39]. Ampli-
con vectors have been used previously to deliver nerve
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growth factor (NGF) to mice that were heterozygous
for a null NGF gene (ngf(+/–) and it was found that
improvements in spatial learning could be quanti-
fied [13]. HSV amplicon-mediated transductions have
been used to deliver genes such as neurotrophin-3 to
protect murine spiral ganglion neurons from cisplatin-
-induced damage both in vitro [14] and in vivo [9].
HSV-1 amplicons have also been used for gene ther-
apy of malignancies and it has been shown that help-
er virus-free HSV-1 amplicon preparations are bet-
ter suited for immunotherapy [62, 63, 72] and leu-
kaemia [61]. Other uses of this viral-based gene de-
livery method have included glucocorticoid-regulat-
ed VEGF expression [24] and human immunodefi-
ciency virus type 1 gp120 expression [27, 70]. Im-
munological responses to this HSV-1 vector have
been described [12] and vectors that are helper vi-
rus-free trigger a much diminished response [44].
Given the interest in developing new models as
well as treatments for diseases such as PD, the ex-
periments used here involved inoculation of the vi-
ruses or the direct injection of plasmids into the
dopamine (DA) producing SN area. In the present
study we utilised 4 different intra-brain gene trans-
fer methods, employing two HSV-1 derived vectors
and two plasmid transfection techniques. The effi-
cacy of different gene transfer protocols was evalu-
ated using lacZ as the reporter gene. The effective-
ness of the non-viral polyethyleneimine (PEI) proto-
col and the amplicon viral method was also con-
firmed by transfecting a mutant gene coding for
FGFR1(TK–) [48] and then showing its effects on neu-
ronal survival.
Our interest in the FGFR1 stems from work by
Tooyama et al. [64], who found that in all PD pa-
tients examined the content of the primary growth
factor that binds the FGFR1, fibroblast growth fac-
tor-2 (FGF-2), becomes depleted prior to cell degen-
eration in SN DA neurons. FGF-2 depletion was not
observed in aged non-Parkinsonian individuals [65],
indicating that FGF-2 defect is specifically associat-
ed with PD.  Even though there may not be a reduc-
tion in the content of the FGF receptors, including
FGFR1 [69], there could still be a disruption of the
signalling produced by this receptor. Therefore,
FGFR1 receptor disruption in SN of Parkinsonian pa-
tients could play a role in the loss of DA neurons
associated with that disease.
In order to inhibit the FGF signalling, we have
been using a dominant negative receptor mutant of
fibroblast growth factor type 1 with a deleted ty-
rosine kinase domain [FGFR1(TK–)], which forms non-
functional heterodimers with any of 3 FGFR1-3, thus
eliminating the signalling by the wild type FGFR’s [67].
In vitro, we found in rat sympathetic neurons that
PEI-transfected FGFR1(TK–) inhibited bone morpho-
genetic protein-7 (BMP-7) induced dendritic growth
[28, 29] and cAMP-induced axonal outgrowth in
human neuronal precursor cells [54, 56]. In glioma
FGFR1(TK–) inhibited cell proliferation [55, 56].
In vivo we tested the hypothesis that diminished FGF
signalling may be a contributing factor in the etiolo-
gy of PD and showed that transfection of the
FGFR1(TK–) can decrease the number of TH-positive
neurons in SN and the concentration of DA in the
striatum of rats (manuscript in press) [17].
Here we show our data for 2 HSV-1 viral methods
and for PEI and calcium phosphate nanopartical
methods. In addition, we also show the effect of
FGFR1(TK–) transfection on SN cells.
MATERIAL AND METHODS
Plasmids
pcDNA3.1-FGFR1(TK–) expressing FGF receptor-1
with deleted tyrosine kinase domain and pCMVpcMV-
-b-gal expressing b-galactosidase cDNA from the cy-
tomegalovirus (CMV) late promoter have been de-
scribed previously [48, 49, 54]. The plasmids were
isolated and purified using a QIAGEN (Valencia, CA)
endotoxin-free kit.
Preparation of PEI
PEI/DNA complexes were prepared using ExGen
500, (MBI Fermentas Inc.), a cationic linear PEI poly-
mer. Freshly prepared mixtures of plasmid DNA and
PEI dissolved in 5% glucose were used. These con-
sisted of 3–5 ml containing 1.5–3.0 mg of plasmid
DNA and 6 PEI equivalents of DNA (one equivalence =
= amount of PEI required to neutralise the negative
charges of DNA phosphate groups).
The complexation of PEI with plasmid DNA was
carried out in 2 stages, using sterile chemicals in
a sterile chamber. In the first stage, plasmid DNAs
(pCMV-b-gal and pcDNAFGFR1(TK–) of known con-
centrations) were mixed with 15% aqueous dextrose
solution and water to get a final DNA concentration
of 0.6 mg/ml. After brief vortexing and centrifuga-
tion, the solutions were kept on ice for 12 hours. In
the second stage, carried out just before surgery,
25 ml of the 0.6 mg/ml DNA solutions were mixed
with 2.7 ml and 3.6 ml of ExGen500 PEI solutions to
obtain PEI-DNA complexes of 6 and 8 equivalents,
respectively. The final dextrose concentration in the
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solutions was 5%. After brief vortexing and centrif-
ugation, the solutions were kept at room tempera-
ture for 10 min prior to injection in the rat brain.
Preparation of the calcium
phosphate nanoparticles
Sodium bis(ethylhexyl) sulphosuccinate (AOT) of
0.1 M in hexane was prepared. In 25 ml of AOT in
hexane 50 ml of aqueous solution of CaCl2 (20% w/v),
400 ml of double distilled water and 10 mg of plas-
mid DNA were dissolved by continuous stirring for
72 h to form a microemulsion A. In another 25 ml of
AOT in hexane 50 ml of aqueous solution of Na2HPO4
(5% w/v), 350 ml of double distilled water, 50 ml of
0.2 M Tris-HCl buffer (pH 6) and 10 ml of plasmid
DNA were dissolved by continuous stirring for 48 h
to form a microemulsion B. Both the microemulsions
were optically clear solutions. Microemulsion B was
then slowly added to microemulsion A at 5 ml/h with
continuous stirring at 8–10oC. The resulting solution
was then further stirred for another 6 h, after which
it was centrifuged at 8 × 103 rpm for 30 min. The
pelletted nanoparticles were washed with hexane
3 times and finally redispersed in 10 ml of double
distilled water by sonication (frequency 22 kHz, power
120 W) for 2 h. The dispersed nanoparticles were dia-
lysed for 10 h and were kept at –4oC for further use.
Preparation of the amplicon virus
Cell culture. Neonatal hamster kidney (BHK) and
RR1 cell lines were maintained as previously describ-
ed [38]. The NIH-3T3 mouse fibroblast cell line was
originally obtained from American Type Culture Collec-
tion and maintained in Dulbecco’s modified Eagle me-
dium with the addition of 10% foetal bovine serum.
Amplicon construction. The coding sequence for
E. coli b-galactosidase was cloned into an HSV ampl-
icon plasmid vector as previously described [21].
Helper virus-based amplicon packaging. Am-
plicon DNA was packaged into HSV-1 particles by
transfecting 5 mg of plasmid DNA into RR1 cells with
Lipofectamine as recommended by the manufactur-
er (Gibco-BRL). Following incubation for 24 h, the
transfected monolayer was superinfected with the
HSV strain 17-derived IE3 deletion mutant virus
D30EBA [46] at a multiplicity of infection (MOI) of
0.2. Once cytopathic changes were observed in the
infected monolayer, the cells were harvested, freeze-
thawed, and sonicated using a cup sonicator (Miso-
nix, Inc.). Viral supernatants were clarified by cen-
trifugation at 5,000 × g for 10 min prior to repeat
passage on RR1 cells. This second viral passage was
harvested as above and frozen. The frozen virus sam-
ples were thawed on ice and sonicated on ice
3 times in a cup sonicator for 30 s. The sample was
centrifuged twice at 2000 × g for 10 min to pellet
cellular debris and the supernatant was retained. The
clarified viral supernatant was then applied to the
top of the 30% layer of a 30%/60% discontinuous
sucrose gradient and centrifuged at 106,000 × g at 4°C
for 1 h. The viral band appearing at the interface
between the 30% and 60% layers was carefully ex-
tracted. The virus was subsequently concentrated via
centrifugation through a 30% sucrose cushion at
106,000 × g at 4°C for 30 min.  Viral pellets were
resuspended in PBS (Ca2+ and Mg2+ free) and stored
at –80°C for future use. HSV-1 amplicon expression
titer was 8.03 × 107 blue-forming units per ml (bfu/ml)
and the helper virus titer was 3.6 × 107 plaque-form-
ing units per ml (pfu/ml) as determined by X-gal his-
tochemistry on transduced NIH 3T3 cells and plaque-
forming assays on transduced RR1 cells. The frequen-
cy of wild-type virus reversion was determined to be
1 in 106 pfu as examined by plaque assays on the
non-complementing Vero cell line.
Helper virus-free amplicon packaging (HF-HSV).
Amplicon stocks were also prepared using a modi-
fied helper virus-free packaging method [10]. The
packaging system utilises a bacterial artificial chro-
mosome (BAC; kindly provided by C. Strathdee) that
contains HSV genome without its cognate packag-
ing (pac) signals as a co-transfection reagent with
amplicon DNA. Because the amplicon vector possess-
es a pac signal, only the amplicon genome can be
packaged. Briefly, on the day prior to transfection
2 × 107 BHK cells were seeded in a T-150 flask and
incubated overnight at 37°C. On the day of transfec-
tion, 1.8 ml Opti-MEM (Gibco-BRL), 25 mg of pBAC-V2
DNA [57], 7 mg of pBS(vhs), and 7 mg amplicon vec-
tor DNA were combined in a sterile polypropylene
tube. Over a period of 30 s 70 ml of Lipofectamine
Plus Reagent (Gibco-BRL) was added to DNA mix and
allowed to incubate at 22°C for 20 min. In a separate
tube 100 ml Lipofectamine (Gibco-BRL) was mixed
with 1.8 ml Opti-MEM and also incubated at 22°C
for 20 min. Following the incubations, the contents
of the 2 tubes were combined over a period of 30 s
and incubated for an additional 20 min at 22°C.
During this second incubation the media in the seed-
ed T-150 flask was removed and replaced with
14 ml Opti-MEM. The transfection mix was added to
the flask and allowed to incubate at 37°C for 5 h.
The transfection mix was then diluted with an equal
volume of DMEM plus 20% FBS and 2 mM hexame-
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thylene bis-acetamide (HMBA) and incubated over-
night at 34°C. On the following day the medium was
removed and replaced with DMEM plus 10% FBS and
2 mM HMBA. The packaging flask was incubated
for an additional 3 days before the virus was har-
vested and stored at –80°C until purification. Viral
preparations were subsequently purified and con-
centrated as for helper virus-containing stocks. Ex-
pression titers were determined by enumeration of
X-gal-positive NIH 3T3 cells transduced with serial
dilutions of amplicon stocks. Wild-type reversion fre-
quency was found to be less than 1 in 107 expressing
amplicon particles as determined by plaque assay on
transduced Vero cells.
Preparation of the amplicon
containing FGFR1(TK–)
FGFR1(TK–) cDNA with deleted tyrosine kinase
region (TK) was cloned into pHSVPrPUC parent am-
plicon plasmid using standard procedures. Helper
virus-free HSV FGFR1(TK–) amplicon stocks were pre-
pared as described above.
Preparation of HSV-1 8117/43 and KD6
The HSV 8117/43 construct utilised in this expe-
riment was created by deleting the ICP4 gene from
the non-replicating HSV vector and inserting the
Mouse Moloney Leukemia virus (MoMuLV) long ter-
minal region (LTR) promoter, a gene essential for
replication, which is a transcription unit that repla-
ces both copies of the ICP4 gene [19, 40, 53].  Briefly,
the construct 8117/43 contains the E. coli lacZ re-
porter gene driven by the MoMuLV LTR in place of
the deleted ICP4. It also has a 2.3 kb BstEII deletion
in the LAT (latency associated transcript) promoter
region. The control construct, KD6, contains the same
deletion but lacks the lacZ insert. Both KD6 and 8117/43
were propagated on the E5-complementing cell line,
a generous gift of N. DeLuca.  Infected cells were
harvested and concentrated by centrifugation at
10,000 × g (30 min at 4oC) and resuspended in
1/100 of the original cell culture volume in MEM with
10% FBS. Vector was released from the infected cells
and subjected to 2 rounds of freeze-thawing. The
stocks were clarified by centrifugation for 2 min at
10,000 × g, and the supernatant aliquoted and fro-
zen at –80oC. Stocks were titrated on complement-
ing E5 cells and the number of ICP4(+) revertants
determined by passage and titration on RS cells (non-
permissive for ICP4(–). All stocks used in this study
had < 1 revertant per 1 × 106 PFU of ICP4(–) plaques,
as determined by differential analyses on E5 (com-
plementing) vs. RS (non-complementing cell lines.
The amounts of virus used in specific experiments
are shown in the captions to the figures.
Animals
Adult Male Fischer 344 rats (Harlan Sprague-Daw-
ley Inc., NIA colony) with an average body weight of
180–250 g were used. The animals were housed in
the Laboratory Animal Facilities in the School of
Medicine and Biomedical Sciences at the State Uni-
versity of New York at Buffalo. The rats were anaes-
thetised with a mixture of ketamine (100 mg/ml),
xylazine (20 mg/ml), and ace-promazine (10 mg/ml)
in 0.9% NaCl (0.2 ml/100 g body weight, i.p.) placed
in stereotaxic apparatus and received unilateral or
bilateral injections (depending on the experiment)
into the SN region of the brain at the co-ordinates
of –5.6 mm (posterior), ± 1.5 mm (lateral), –8.2 mm
(ventral) from the bregma [47]. Each injection deli-
vered 3 to 5 ml of solution to each site at a rate of
0.5 ml/min by means of a 30 G stainless steel needle
on a 10 ml Hamilton syringe held by the microman-
ipulator on the stereotaxic apparatus. The needle was
slowly removed 5 min after the completion of the
injection. The wound was then sutured. All proce-
dures were approved by the Institutional Animal Care
and Use Committee guidelines (IACUC) of the State
University of New York at Buffalo. For HSV-1 (8117/43)
injections 4 ml containing 2 × 106 plaque-forming units
(pfu) was injected per site. For the amplicon helper-
free 1.92 × 105 pfu/4 ml was injected. For HSV-1
amplicon (1.3 × 105 pfu/4 ml) containing the helper
virus, 1.4 × 105 pfu/4 ml was injected.
Tissue preparation and histochemical
detection of b-galactosidase activity
The rats were deeply anaesthetised (as described
above for surgery) and were perfused transcardially
with PBS (pH 7.4) followed immediately by ice-cold
fresh 4% paraformaldehyde fixative in 0.2 M phos-
phate-buffer (pH 7.4). The brains were removed,
placed in the paraformaldehyde fixative solution then
cut into 2-mm coronal sections using a stainless steel
brain mould. These sections were post-fixed with 2%
formaldehyde, 0.2% glutaraldehyde, 0.01% NaDOC
(sodium deoxycholate) and 0.02% NP-40 for 1 h at
4oC. The tissue was then washed twice with PBS fol-
lowed by 3% DMSO/PBS. The X-gal staining solution
consisted of 0.87 g NaCl, 100 mM HEPES, pH 7.5,
2 mM MgCl2, 0.01% NaDOC, 0.02% NP-40, 5 mM
potassium ferricyanide and 5 mM potassium ferro-
cyanide. This solution was freshly prepared and kept
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at 4oC. When ready to use, the solution was warmed
to 36oC and 5 ml of 2% X-gal [5-bromo-4-chloro-3-
-indolyl b-D-galactopyranoside] in dimethyl forma-
mide were added. The tissue sections were stained
with X-gal for 7 h at 31oC in the dark. Subsequently
the slices were washed several times in PBS and
placed in 30% sucrose in PBS. All solutions were pre-
pared fresh and their pH was adjusted to 7.3 in or-
der to prevent the detection of endogenous (acidic)
b-galactosidase. Sections were photographed either
with a digital camera or laid on transparency film
and scanned at high resolution.
Following photography, tissues were cryoprotect-
ed with 20% sucrose and then further cut into
50-mm sections using a freezing stage microtome. Brain
sections were mounted onto glass slides, counterstained
with Eosin Y, dehydrated and coverslipped. Sections were
photographed on an Edge 400 microscope.
Tyrosine hydroxylase (TH) immunostaining
Tissue staining was performed using rabbit anti-TH
antibody (Chemicon, cat#AB151). Sections were
pre-incubated in a blocking solution of 10% bovine
serum albumin (BSA) in PBS for 50 min at room tem-
perature and incubated in anti-mouse primary anti-
body (1000:1) overnight in 1% BSA in PBS at 4oC.
Sections were then washed 3 times at 2 min per wash
with PBS to remove primary antibody, and incubat-
ed in biotinylated anti-rabbit secondary antibody at
a 100:1 ratio for 50 min at room temperature in
a 1% BSA in PBS and washed 3 times at 2 min per
wash. The sections were then washed in 3% hydro-
gen peroxide for 5 min and PBS, again 3 times at
2 min. The sections were then incubated with extra
avidin-HRP (ABC) for 50 min at a 100:1 ratio at room
temperature in 1% BSA in PBS followed by 2 washes
with PBS and 2 with dH2O at 2 min per wash. Stain-
ing was completed with diaminobenzidine (DAB) for
2 to 5 min until stains appeared followed by 2 washes
with distilled H2O and 2 with PBS at 2 min per wash.
In some cases nickel intensification was used. Fol-
lowing completion of the staining procedures, sec-
tions were mounted on slides and coverslipped for
examination using a light microscope.
Cell size measurements
During the cutting and mounting of the brain
sections (in the coronal plane), the right side of the
brain was marked by punching a small needle hole
through a part of the brain distant to SN (such as
the cortex and upper right midbrain area). Each sec-
tion of the brain was kept and systemically stored.
Every 5th section was stained and mounted in se-
quential order. The level of each section was eval-
uated using the co-ordinates from Paxinos and
Watson [47].
Digital photomicroscopy was used to capture
representative regions of SN of 50-mm-thick brain
sections that were stained with tyrosine hydroxylase
immunostaining. A section closest to –5.6 mm AP
was chosen, since this is the approximate location
of the injection.  The microscope was focused on
the area of the SNpc closest to the injection co-ordi-
nates of ± 1.5 mm LM, –5.6 mm AP and –8.2 mm
DV and the areas of the 5 closest cells were mea-
sured using NIH shareware program Image J. This
was done for the left and right side of the same brain
section. Since tissue sections can differ in size from
each other as a result of varying degrees of shrink-
age following staining, processing and dehydration,
the average area on the experimental side was di-
vided by the control (or non-injected) side and ex-
presses as a percentage.
RESULTS
Injection of the lacZ reporter gene (b-galactosi-
dase) into SN was employed to visualise the trans-
fection. The X-gal staining procedure detects ex-
pressed b-galactosidase activity when the b-galac-
tosidase enzyme cleaves the X-gal substrate into
a blue product molecule that precipitates onto the
tissue.  No staining was observed in controls injected
with glucose at 1 week (Fig. 1A, panel I) or 1 month
(not shown), although expression of the transfected
genes was seen with the full size 8117/43 HSV-1 in-
oculated into rat brains, resulting in modest stain-
ing in the ventral midbrain region 1 week post injec-
tion (Fig. 1A, panel II) and strong staining 1 month
post injection (Fig. 1A, panel III). Figure 1B shows
photomicrographs of staining in SN in 50-mm-thick
sections. One week following inoculation with con-
trol HSV-1 (KD6) lacking the lacZ reporter gene, no
b-galactosidase activity was detected (Fig. 1B, panel I),
whereas 1 week following inoculation with the lacZ-
-containing recombinant (8117/43) we observed
a number of cells expressing b-galactosidase activity
(Fig. 1B, panel II). An enlarged view of a typical
X-gal-positive neuron in the zona compacta of SN is
depicted (Fig. 1B, panel III).  It is important to note
that no b-gal expressing cells with astrocytic mor-
phology were observed. Interestingly, over time the
expression of b-galactosidase activity increased,
and 1 month after inoculation, a greater number
of cells showed strong b-galactosidase activity
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(Fig. 1B, panel IV). On the basis of these results we
conclude that HSV-1 ICP4(–) vector can be used effec-
tively to express a recombinant gene within the rat SN.
An attractive alternative to the full size virus is
the HSV-1 amplicon, which is a minimised derivative
of the full size HSV-1, owing to the fact that it may
potentially have less of a toxic effect on cells. HSV-1
amplicon-mediated b-galactosidase gene transfer
into SN region is illustrated in Figure 2. At the
1 week post-injection time point only minimal X-gal
staining was visible on 2-mm tissue slabs (previously
published, not shown here) [17], although the use
of a “helper virus” significantly increased the level
of staining. After only 1 week, even in the gross sec-
tions, significant staining is evident (panels I and II).
This result was not surprising as the titers of the help-
er virus-packaged amplicon stocks are typically
10-fold higher than the helper-free stocks. Panel III
Figure 1. Brains of 3-month-old male Sprague-Dawley rats inoculated with HSV-1 (8117/43) [4 ml, 2 × 106 plaque forming units (pfu) per
injection site]. A. X-gal staining of 2-mm-thick coronal slabs of rat midbrain 1 week following bilateral injections of 5% dextrose (panel I),
1 week following bilateral injections of HSV-1 8117/43 vector expressing b-galactosidase (middle photograph), and 1 month following
bilateral injections of the same virus. The 1 month time point showed the greatest level of expression. B. Photomicrographs of X-gal
stained 50-mm rat midbrain sections are shown. One week after inoculation of control KD6 HSV1 [(I) tissue was counterstained with eosin
to visualise the cells] or b-galactosidase expressing 8117/43 HSV-1 (II). An enlarged 8117/43 HSV-1 infected SN neuron is shown (III).
One month post infection of 8117/43 HSV-1 (IV). The scale bar represents 100 mm.
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shows the typical neuronal morphology of SN cells
expressing b-galactosidase activity. In contrast, with-
out the helper virus, there is only minimal staining
1 week following injection (panel IV), although
1 month post inoculation, obvious and significant
X-gal staining was observed both on 2-mm tissue
Figure 2. Brains of rats inoculated with amplicon vector with helper virus (panels I, II and III) and without helper virus (panels IV and V).
Inoculation of HSV-1 amplicon (1.3 × 105 pfu/4 ml) containing the helper virus (1.4 × 105 pfu/4 ml). At 1 week post inoculation the ex-
pression of b-gal activity was visible on 2-mm tissue slabs. Panel I shows injections (from left to right) of 1 and 2 ml and panel II, 3 and 4 ml
of viral solution. Panel III shows a high magnification photomicrograph of infected SN cells with typical neuronal morphology on a 50-mm
section.  Panels IV and V show helper-free amplicon HSV-1 virus inoculation (1.92 × 105 pfu/4 ml) at 1 week post inoculation (panel IV)
and 1 month post inoculation (Panel V) on 50-mm sections. Minimal staining was seen at 1 week (panel IV) but significant b-gal staining
was detected after 1 month (panel V). The scale bar represents 100 mm. Panels IV and V are derived from [16] with kind permission from
Molecular Brain Research (Elsevier).
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slabs (not shown) and 50-mm sections in the area
adjacent to the injection site (panel IV).
We also explored 2 non-viral methods. The first
was the calcium phosphate nanoparticle method.
Calcium phosphate nanoparticle pCMV transfection
did not result in detectable b-galactosidase activity
1 week after transfection (n = 3) (Fig. 3, panel I). How-
ever, in rats that were sacrificed 1 month after trans-
fection we observed an unambiguous X-gal staining
in 3 of the 4 rats injected (panel II). The high magnifi-
cation of the 50-mm-thick sections (counterstained
with eosin) clearly shows definite profiles of trans-
fected cells (panels III and IV). Interestingly, the stained
cells are not in the target SN cells but in the adjacent
red nucleus area. The reason for the selective trans-
fection of these cells is not clear at this time.
Our studies with in vivo PEI-transfected pCMVb-gal
plasmid showed the recombinant b-galactosidase
activity both at the 1 week (Fig. 4, panels I, II and III)
and 1 month time points (Fig. 4, panel IV), although
the stain was not as robust as that seen with
HSV1 8117/43 vector. The majority of b-galactosi-
dase expressing cells, such as those detected in SN
region (panel III) as well as in the more dorsal peri-
aqueductal grey matter (panel I), had a neuronal-
like morphology, although a few had an astrocyte-
shaped morphology, as seen in Figure 4, panel II.
Again, at 1 month, a greater number of cells in SN
appear to be positively stained (Fig. 4, panel IV). Over-
all, using PEI, our studies showed variability between
animals, with some transfected predominantly in cells
adjacent to the injection sites, while others had much
higher levels of b-galactosidase activity with a broader
distribution in SN region.
On the basis of the above information, we used
2 of these 4 methods to deliver the defective
FGFR1(TK–) gene in vivo. Tooyama previously observed
a decrease in fibroblast growth factor-2 (FGF-2) in
SN-DA neurons prior to cell degeneration in all Par-
kinson’s patients examined [64]. We hypothesised,
therefore, that decreased signalling by FGF-2’s main
receptor, FGFR1, might play a role in the neuronal
degeneration observed in PD. As a test of this hy-
pothesis, we delivered the dominant negative
Figure 3. Transfection of pCMV-bgal using calcium phosphate nanoparticles. Rats injected with 4 ml of calcium phosphate nanoparti-
cles/pCMV-b-gal per SN site. One week post transfection no staining was observed — 2-mm tissue slab (I). 1 month post transfection
— representative 50-um whole brain section (II) shows b-gal activity in the area of the red nuclei typical for calcium phosphate nanopar-
ticle transfection. III and IV high magnification photographs of cells in the red nuclei areas on both sides of the brain. The scale bar repre-
sents 100 mm.
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FGFR1 mutant, FGFR1(TK–), which lacks the tyrosine
kinase domain [48, 49]. The non-viral PEI was used
but the calcium phosphate method needed more
development, since it did not target SN. Both of the
viral methods worked well, although we used the
amplicon rather than the full size 8117/43 HSV-1 as it
allowed faster construction of FGFR1(TK–)-express-
ing virus.
Figure 5 shows that a decreased number of
TH-positive cells can be seen on FGFR1(TK–) injected
side. We observed a similar result using the helper-
free HSV-1 amplicon as a FGFR1(TK–) DNA delivery
vector and have previously reported a statistically sig-
nificant difference [17].
To ascertain how viral transfection affected cell
size; we performed cell area measurements for cells
Figure 4. PEI-mediated transfection of pCMV b-gal. Rats transfected with 4 ml of PEI/b-gal and PEI/pcDNA into the SN area. One week
post injection: 50-mm midbrain sections showing b-gal expressing cells in periaqueductal grey (I), astrocyte-shaped cell in ventral mid-
brain (II) and neuronal-like cells in substantia nigra area (III). One month after transfection: the relatively large number of cells shows
b-gal activity in the substantia nigra (IV). The scale bar represents 100 mm. Panels III and IV were derived from [16] with kind permission
from Molecular Brain Research (Elsevier).
Figure 5. The effect of the FGFR1(TK–) delivered by PEI. There
are fewer cells on the FGFR1(TK–) side as compared to the con-
trol (b-galactosidase) side. The scale bar represents 100 mm.
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near the injection site. Rats were injected unilateral-
ly with the lacZ-containing amplicon virus or with
FGFR1(TK–). The average cross-sectional area of TH-
-positive cells in the SN on the virus-injected side
had an area of 106.37 ± 9.66% relative to its non-
injected side. FGFR1(TK–) injected side had an aver-
age area of 110.58 ± 3.41% relative to its non-in-
jected side. Table 1 below shows our data.
The comparisons were calculated in 2 ways. The
first method was to simply average all of the area
measurements for each group. These numbers can
be seen in the 2nd row of the table. The area of the
injected side divided by the non-injected side is
shown in the 3rd row.
The second method for calculating the data was
to divide the injected side by the non-injected side
for each microscope slide. The number shown in the
4th row is the average of all these ratios. This meth-
od would negate any variability caused by the shrink-
age of the tissue on the microscope slide during
mounting and dehydration with alcohol and xylene.
As seen, there was virtually no difference in the final
results.
DISCUSSION
The studies presented here have explored the ef-
fectiveness of transfecting reporter genes with dif-
ferent viral and non-viral methods. Our studies have
shown that all 4 methods discussed here were capa-
ble of expressing the lacZ reporter gene effectively
in the adult rat brain. While at this stage viral vec-
tors appear more efficacious than the non-viral meth-
ods used in our study, there are problems inherent
in viral transduction, such as potential immune re-
sponses and pathologies, especially when the im-
mune system is impaired. Since PEI and, especially,
calcium nanoparticles appear to be effective alter-
natives, further development of these non-viral meth-
ods is warranted.
The novel method that we describe here for gene
transfection employs calcium phosphate nanoparti-
cles [51]. We show evidence of in vivo transfections
into the rat brain in general (Fig. 3), although the
staining is not in the target area of SN but rather in
the red nucleus. Future modifications of this meth-
od may be more useful for this specific application
and testing is ongoing.
Gene transfection using commercial PEI prepa-
rations is also effective (Fig. 4). Our results comple-
ment those of an earlier study [42] that successfully
used the PEI method to deliver the dopamine trans-
porter gene to cells of the SN. Taken together, the
results show that PEI transfection does work,
although the efficacy of gene delivery varies from
experiment to experiment, which could reflect differ-
ences between the batches of polymer or difficulty
in controlling experimental variables. In addition, this
method was significantly less effective than a recently
reported brain gene transfer using organically mod-
ified silica nanoparticles [18]. Further improvements
in PEI method are thus required. We used the
22 kDa PEI, since it was reported that the small size
PEIs appear to be superior to the larger size mole-
cules in gene transfection [34, 35]. Since it has been
reported that low molecular weight PEI’s, 0.5–10 kDa
made by fractionating commercially available 25 kDa PEI,
were shown to have a better rate of transfection and
were less cytotoxic than the unfractionated 25 kDa PEI
by itself [3], future improvements will take these ideas
into account as well as others, such as a report show-
ing the increasing effectiveness of DNA/PEI delivery
using a slow release delivery system that delivers
DNA/PEI complexes for several days [52]. There are
several reports demonstrating chemical modifica-
tions of PEI’s have been shown superior transfection
over the non-modified PEI’s [2, 30, 43, 60, 73, 74].
Another concern deals with studies by others on
the mechanism of PEI gene delivery, indicating that
a relatively small fraction of DNA/PEI complexes reach
the nucleus [4].
In the present study, the non-replicating HSV-1
8117/43 construct, in which the lacZ gene is driven
by combined LAT and MoMuLV LTR promoters, gave
the strongest signal following delivery of this reporter
Table 1. Average size of cells
Non-injected side of b-galactosidase Non-injected side FGFR1(TK–)
 b-galactosidase side  injected side of FGFR1(TK–) injected side of
Average cell area measurements (pixels) 6540.04 ± 554.76 7003.76 ± 1202.16 7645.63 ± 508.56 8438.367 ± 549.68
Change relative to non-injected side 107.09% 110.37%
The average of the relative percentage 106.37 ± 9.66% 110.58 ± 3.41%
for each animal
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gene (Fig. 1). This complements other studies, which
use this vector as a delivery vehicle to a number of
distinct sites within CNS [6, 59], specifically SN [40]
and hippocampus [7]. Early reports with HSV vec-
tors have showed decreased reporter gene expres-
sion during latent infection with HSV LAT promoter
constructs [41]. However, introduction of the tandem
MoMuLV LTR/LAT promoters increased the efficiency
and duration of reporter gene expression [7, 37].
For HSV-1 8117/43 the length of expression and
the number of cells expressing the reporter gene are
both significant and useful, more for acute basic
applications. These may include in vivo intracerebral
gene transfer to investigate underlying mechanisms
and potential corrective therapies for neurodegen-
erative diseases, especially those involving the nigros-
triatal pathway.
Another promising development has been the
construction of the amplicon HSV-1 vector. Although
the effect observed with this vector (Fig. 2) was not
as robust as the 8117/43 HSV-1 (Fig. 1), it is impor-
tant to note that the 8117/43 HSV-1 could be inocu-
lated at a titer approximately 10 times higher than
the amplicon virus as a result of its ability to be pro-
duced at higher titers without a helper virus. How-
ever, the efficacy of gene expression of the ampli-
con was significantly enhanced when used with
a helper virus (Fig. 2, panels I, II and III). Thus, in
biological experiments in which maximally effective
gene delivery is essential, it may be advantageous to
use a helper virus containing amplicon preparations.
The use of the amplicon to deliver FGFR1(TK–)
showed a highly reproducible effect from one ani-
mal to the next [17]. Cell counts of all TH-positive
cells in SN of rats injected on only one side of the
brain showed a significant decrease on FGFR1(TK–)
side compared to the non-injected side [17]. There was
no significant difference between the numbers of
TH-positive cells on the b-galactosidase injected side
compared to its non-injected side. A comparison of
the b-galactosidase injected rats compared to
FGFR(TK–) rats showed a decrease in the number of
cells [17]. A similar decrease was observed with PEI-
-transfected FGFR1(TK–), although these results were
not statistically significant because of the great indi-
vidual variation within groups.
Another outcome of this study was that HSV-1
vectors expressed the transgene exclusively in neu-
ronal like cells, whereas PEI expressed the transgene
both in neurons and in glial cells (Fig. 4). Hence non-
viral methods may be advantageous when gene
transfer to different types of brain cell is required.
This finding is consistent with the tenet that viral
transfected cells (recombinant adeno-associated
virus-2) were mostly neurons, where the non-viral
methods tended to target both neurons and glia [26].
Given that HSV-1 infections, which appeared to be
exclusively neuronal, had a similar effect on TH neu-
rons as PEI transfection, it is likely that the effects of
FGFR1(TK–) were produced directly in SN neurons.
We have further found (Table 1) that the cells on the
virus-injected side might be slightly larger, although
the increase is not statistically convincing.
Our interest in this work stems from the fact that
progress in treating diseases like PD is hampered by
the lack of animal models that mimic progressive
and specific degeneration of the dopaminergic (DA)
neurons of SN, as well as by an insufficient under-
standing of the mechanisms leading to neuronal
death. Since there are rare familial cases of PD asso-
ciated with mutations in the synuclein or the parkin
genes [25, 31, 32], we have an interest in other gene
malfunctions that could play a role in PD.
In summary, both viral and non-viral methods are
effective in introducing functional recombinant
genes into CNS. These methods should be further
developed to improve their efficacy and reduce po-
tential tissue damaging effects. These methods may
be a valuable alternative to transgenic animals in
developing new disease models and testing new ther-
apeutic approaches.
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